Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

Shares of Biogen Inc. BIIB advanced 5.65% to $120.49 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 9.52% to 5,456.90 and ...

The blue-chip Dow Jones was cautiously higher at the opening bell on Wednesday as Donald Trump's tit-for-tat tariff war with ...

The S&P 500 Index ($SPX) (SPY) today is up +0.64%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.29%, and the Nasdaq ...

In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Morgan Stanley lowered the firm’s price target on Biogen (BIIB) to $152 from $157 and keeps an Equal Weight rating on the shares. The firm ...

Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline. Read why SAGE ...

Shares of Biogen Inc. BIIB slipped 4.31% to $114.05 Tuesday, on what proved to be an all-around poor trading session for the ...

Biogen Inc. (NASDAQ:BIIB – Get Free Report) has been given a consensus rating of “Hold” by the thirty-one brokerages that are ...

Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR). Over the next few years, ...

Biogen (NASDAQ:BIIB – Get Free Report) was downgraded by Argus from a “buy” rating to a “hold” rating in a report released on ...